Celecoxib

Name: Celecoxib
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (62 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261 Synonyms: SC 58635

62 publications

CAS No. 169590-42-5

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib has been cited by 62 publications

Int J Mol Sci, 2021, 22(3)1194

PubMed: 33530480 ( click the link to review the publication )

J Clin Invest, 2020, 26;132417

PubMed: 32452837 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6299

PubMed: 33288764 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6339

PubMed: 33311482 ( click the link to review the publication )

Cell Death Differ, 2020, 20

PubMed: 32433558 ( click the link to review the publication )

Nanotoxicology, 2020, 14(2):162-180

PubMed: 31703536 ( click the link to review the publication )

Cells, 2020, 14;9(5):E1222

PubMed: 32423044 ( click the link to review the publication )

Aging (Albany NY), 2020, 12

PubMed: 33180744 ( click the link to review the publication )

Neoplasia, 2020, 22(11):576-589

PubMed: 32980776 ( click the link to review the publication )

J Inflamm Res, 2020, 13:1043-1055

PubMed: 33293848 ( click the link to review the publication )

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Brain Res, 2020, 20;1740:146846

PubMed: 32325074 ( click the link to review the publication )

AAPS PharmSciTech, 2020, 17;21(5):135

PubMed: 32419073 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):626

PubMed: 32796811 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

EBioMedicine, 2019, 47:142-155

PubMed: 31492557 ( click the link to review the publication )

Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )
Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Front Pediatr, 2019, 7:228

PubMed: 31231624 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Chin J Dent Res, 2019, 22(4):221-227

PubMed: 31859282 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Theranostics, 2018,

PubMed: 30083255 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245915 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )
Oncotarget, 2017, 8(31):51748-51757

PubMed: 28881683 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80651-80665

PubMed: 29113333 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncotarget, 2016, 7(19):28435-47

PubMed: 27078846 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	MnP0SpVv[3Srb36gRZN{[Xl?	Mn;tNE4yNTNyIN88US=>	NYWyZlZUPDhiaB?=		M3fTcIlv\HWlZYOgTWNCVS1zIHX4dJJme3Orb36gc44h[m:2aDDwdo91\WmwIHHu[EBuWk6DIHzleoVt	NUTxcYV6OjZ3MUOxO\|I>
H460	M1ztWmZ2dmO2aX;uJGF{e2G7	MnfPNE4yNTNyIN88US=>	Ml\aOFghcA>?		MljRbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw>	NWPVN5c6OjZ3MUOxO\|I>
HKESC-2	M{Ozemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1Hhe\|IxyqEQvF2=	M4rrblQ5yqCqwrC=		M1rNSJNq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>?	NYK2[ng5OjZ2N{S2PVM>
CaES-17	MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DIPVIxyqEQvF2=	NGLxfos1QMLiaNMg		M333XZNq\26rZnnjZY51dHliaX7jdoVie2W\|IITo[UBKSzVywrD2ZYx2\XNib3[gc5hidGmybHH0bY7DqA>?	M1rQdVI3PDd2Nkmz
HKESC-2	MXfBdI9xfG:\|aYOgRZN{[Xl?	NVHNUXhiOjEEoN88US=>	M2fNW\|Q5yqCqwrC=		NELUPFZz\WS3Y3XzJI95[WyrcHzheIlvNWmwZIXj[YQh[XCxcITvd4l{	NEC0PYgzPjR5NE[5Ny=>
CaES-17	NFPWW5pCeG:ydH;zbZMhSXO\|YYm=	M4XyNVIxyqEQvF2=	NV7ETWJEPDkEoHlCpC=>		M4WxfJJm\HWlZYOgc5hidGmybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM>	MXmyOlQ4PDZ7Mx?=
A549	MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTFSYo2NTF4MDFOwG0>	M3jwdlQ5yqCqwrC=	MnXTSG1UVw>?	MoD6TWM2OD1zNkOuOEDPxE1?	MofUNlY1PjR4NEO=
HCC827	M3PQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3HwclUuOTZyIN88US=>	M2XMWFQ5yqCqwrC=	MWHEUXNQ	MUXJR\|UxRTZ7LkKg{txO	MWSyOlQ3PDZ2Mx?=
A549	M165VGFxd3C2b4Ppd{BCe3OjeR?=	NUK3fFc3QDBiwsXN	Mom2OFjDqGkEoB?=	MnfDSG1UVw>?	MWPpcoR2[2W\|IHHwc5B1d3Orcx?=	MmfzNlY1PjR4NEO=
HCC827	M4P1fWFxd3C2b4Ppd{BCe3OjeR?=	MkL2PFAhyrWP	M1XRWlQ5yqCqwrC=	NGPmTZhFVVOR	MnvHbY5lfWOnczDhdI9xfG:\|aYO=	NETlPZQzPjR4NE[0Ny=>
SGC-7901/DDP	MUjGeY5kfGmxbjDBd5NigQ>?	NGPaXWgyOMLiwsXN	NFn0OG8zPCCq		M{TKVolvcGmkaYTzJIN6[2yxb4j5[4Vv[XOnLUKgZY5lKFBvZ3z5Z49xem:2ZXnuJIV5eHKnc4Ppc44>	M1XnRVI3PDB5NkWz
SGC-7901	NUXCTnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYXCd3pWOjUEoHlCpC=>		NXj0d45SUUN3ME2xNVUvODhizszN	NXf3UoFwOjZ2MEe2OVM>
SGC-7901/DDP	NV6yVXd4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVS4fo1COjUEoHlCpC=>		NEL5c3ZKSzVyPUO1MlQ2KM7:TR?=	NIrUVG4zPjRyN{[1Ny=>
SGC-7901/DDP	NVLySI9sSXCxcITvd4l{KEG\|c3H5	MYWxNOKhyrWP	NVXXdIx6OjRiaB?=		MUPpcoR2[2W\|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKHerdHigZ4l{eGyjdHnu	M1XUWFI3PDB5NkWz
SGC-7901/DDP	M3\xcGZ2dmO2aX;uJGF{e2G7	NH\2Wm4yOMLiwsXN	NFLHNXozPCCq		NIDVfHNqdmirYnn0d{B1cGViZYjwdoV{e2mxbjDv[kBRNWeueXPvdJJwfGWrbjD0bJJwfWeqIHLsc4NscW6pIFXQNkwh[W6mIHnuZYN1cX[jdHnu[{BRU0FiYX7kJGNTTUMEoB?=	NXv4fpVDOjZ2MEe2OVM>
SGC-7901/DDP	M3W3W2Z2dmO2aX;uJGF{e2G7	NIC3[JcyOMLiwsXN	Mm\TNlQhcA>?		M1vxV4NifXOnczDhJI1iemunZDDk[YNz\WG\|ZTDpckB1cGVibHX2[Ywhd2ZiQnPsMVIheHKxdHXpci=>	M{DhdFI3PDB5NkWz
H357	MlHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXsO{42NzFyIN88US=>	NG[yTIY1QCCq	M2naOWROW09?	Mm\UbY5pcWKrdIOgZ4VtdCCpcn;3eIjDqGOxbXLpcoVlKHerdHigV4FjfXSxY3zhfC=>	MmjPNlYxODl6N{S=
TAF	MlvTSpVv[3Srb36gRZN{[Xl?	MnLBNVDDqML3TR?=	NIDqd2M4KGR?		MWTh[oZm[3S\|IGTBSpMh[WSqZYPpeoUheHKxcHXyeIlmew>?	MomwNlU6QDdzMke=
TAF	Ml3OSpVv[3Srb36gRZN{[Xl?	NWDteJlwOTEEoNM1US=>	MUGzNE0yOjBibXnu		M1LjXJBwd3KueTDh[oZm[3S\|IHTBb5QheGixc4Doc5J6dGG2aX;uJINwdnOncYXlcpQhfG9iRVfGJJNq\26jbHnu[y=>	MYWyOVk5PzF{Nx?=
TAF	MmnGSpVv[3Srb36gRZN{[Xl?	M4\PSVExyqEEtV2=	M2fLeFQ5KGh?		MmHDbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	MWmyOVk5PzF{Nx?=
PANC-1	NHnoWW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1rF[\|IxNzZyL{GwNEDPxE1?	MnHaNlQwPDhxN{KgbC=>		NHLVfI1qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NVHpfIhkOjV7N{OwOlI>
PANC-1	M3fHdGZ2dmO2aX;uJGF{e2G7	MYSyNE83OC9zMECg{txO	MmTZNlQhcA>?		MVTheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	MXSyOVk4OzB4Mh?=
HeLa	NF\S[VRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVH3WIxvOjEEoN88UeKh	MoTjNlTDqGh?		NIixOFFmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbh?=	NEjrWYwzPTd5MESyNy=>
SACC-83	MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvGNlDDqM7:TdMg	NEXFT4wzPMLiaB?=		MYXlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>?	NH;aPXozPTd5MESyNy=>
HeLa	MUjBdI9xfG:\|aYOgRZN{[Xl?	MVuyNOKh\|ryPwrC=	NWHRTo4xOjUEoHi=		MUjlcohidmOnczDyZYRq[XSrb36tbY5lfWOnZDDpcohq[mm2aX;uJI9nKGOnbHygZZBweHSxc3nz	M{DVU\|I2PzdyNEKz
SACC-83	NIHQTZpCeG:ydH;zbZMhSXO\|YYm=	MlXTNlDDqM7:TdMg	M2\KT\|I1yqCq		NIP0PJZmdmijbnPld{Bz[WSrYYTpc44ucW6mdXPl[EBqdmirYnn0bY9vKG:oIHPlcIwh[XCxcITvd4l{	MnnaNlU4PzB2MkO=
HeLa	MnznSpVv[3Srb36gRZN{[Xl?	NVvtZ3gzOjBxNECvPFAh\|ryP	M2HpclI1yqCq		NVjTVmg{fXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R?	M2fhUFI2PzdyNEKz
SACC-83	MWHGeY5kfGmxbjDBd5NigQ>?	MlHwNlAwPDBxOECg{txO	MVSyOOKhcA>?		NXnTeoMyfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R?	MViyOVc4ODR{Mx?=
HLCZ01	MkHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF3yVmYx6oDVNkFCpOK2VQ>?	NXjI[4FFPDhiaB?=	Ml3hSG1UVw>?	M3T4VIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NV:5TIs5OjV5MkS4PVk>
HLCZ01	NU\WZmxHTnWwY4Tpc44hSXO\|YYm=	MVW0NOKh\|ryP	NWjqXJQ5OjRiaB?=	M1LwbGROW09?	NIf0NlBqdmO{ZXHz[ZMh[WOldX31cIF1cW:wIH;mJGcxN0dzLYDoZZNmKGOnbHzzJINwdWKrbnXkJJdqfGhiSV\OMe6y	MlXGNlU4OjR6OUm=
HLCZ01	M4TDc2Fxd3C2b4Ppd{BCe3OjeR?=	NHTmXGQ1OMLizszN	MVeyOEBp	NGXaTlVFVVOR	MYDlcohidmOnczDhdI9xfG:\|aYOgZ49u[mmwZXSge4l1cCCLRl6t{tE>	NWK5V\|hNOjV5MkS4PVk>
HLCZ01	NXTUc5V4TnWwY4Tpc44hSXO\|YYm=	MVi0NOKh\|ryP	NYPzPGJzOjRiaB?=	M2TyTmROW09?	Mmr5bY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x	MofPNlU4OjR6OUm=
MGC803	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TyXlAuPjBizszN	NYX1cGxIPzJiaB?=		NInxTZNKSzVyPUS3MlI26oDLwsJihKk3NjR\|IN88US=>	MnPoNlU4ODF\|N{i=
SGC7901	M4H6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHH6NpgxNTZyIN88US=>	MlvxO\|IhcA>?		MVjJR\|UxRTR\|LkWz5qCKyrIkgJm1MlEzKM7:TR?=	M4LldVI2PzBzM{e4
MGC803	M1HiOmZ2dmO2aX;uJGF{e2G7	MoraOFDDqM7:TR?=	NF\DUIY5NzF4L{K0JIg>		MnvHeZBz\We3bHH0d{BE[mxvYjDlfJBz\XO\|aX;u	NXP3enl7OjV5MEGzO\|g>
SGC7901	MVTGeY5kfGmxbjDBd5NigQ>?	NEjnN5M1OMLizszN	NEXyfYM5NzF4L{K0JIg>		NVTxWW9rfXC{ZXf1cIF1eyCFYnytZkBmgHC{ZYPzbY9v	NWDEPFNMOjV5MEGzO\|g>
MCF-7	NHvjcoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\hNU8yOCEQvF2=	NFjFOFc4OiCq	MnT2SG1UVw>?	NF3zSVNmdmijbnPld{Bk[WylaYTybY9tNWmwZIXj[YQh[2WubDDndo94fGhiaX7obYJqfGmxbh?=	MWiyOVY3PzVzMB?=
MDA-MB-231	M4TBNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;uPFEwOTBizszN	MnrZO\|IhcA>?	NFXYVXJFVVOR	NXfVXI1k\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36=	NX;wTXg4OjV4Nke1NVA>
MDA-MB-231	M17jOmZ2dmO2aX;uJGF{e2G7	MWGwMVQxKML3TR?=	NXnqdms6PC1{NDDo		NUn2WIJzcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MoDjNlU2QDd\|Mkm=
MCF-7	MWDGeY5kfGmxbjDBd5NigQ>?	MojqNE01OCEEtV2=	NVLzOWw4PC1{NDDo		NEfsRnBmdmijbnPld{B1cGViZX\m[YN1eyCxZjDUVGEhd25iQVLDS\|Ih\XiycnXzd4lwdsLi	MnyzNlU2QDd\|Mkm=
MCF7-MX	M2fERWZ2dmO2aX;uJGF{e2G7	M2LGRlAuPDBiwsXN	MX60MVI1KGh?		M{TCSoVvcGGwY3XzJJRp\SCnZn\lZ5R{KG:oIGTQRUBwdiCDQlPHNkBmgHC{ZYPzbY9vyqB?	NUjCOFVFOjV3OEezNlk>
MDA-MB-231	NECyd4xHfW6ldHnvckBCe3OjeR?=	M1\4eVAuPDBiwsXN	Mke0OE0zPCCq		NICw[IV{fGmvdXzheIV{KHSqZTDlfJBz\XO\|aX;uJI9nKEGEQ1eyJJVxKHSxIESuNlchfGmvZYOgeI8h[2:wdILvcEBt\X[nbDDifUAyOiCqwrC=	NHXrR4szPTV6N{OyPS=>
A2780	NW[yUWpnTnWwY4Tpc44hSXO\|YYm=	NXr3ZVlRPS9zMD:xOUDPxE1?	MWe0PEBp		MmrU[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NFvQOJEzPTR{NEi5PC=>
SKOV3	NHnaT4xHfW6ldHnvckBCe3OjeR?=	NIWzSYc2NzFyL{G1JO69VQ>?	NXjRV5hEPDhiaB?=		NXXQRWVT\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M1HRV\|I2PDJ2OEm4
A2780	NWfHOZhJTnWwY4Tpc44hSXO\|YYm=	M1vlPFUwOTBxMUWg{txO	M2XycVQ5KGh?		M4\2SYVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5?	MV2yOVQzPDh7OB?=
SKOV3	MmLBSpVv[3Srb36gRZN{[Xl?	NVLDbVJFPS9zMD:xOUDPxE1?	M4ra[FQ5KGh?		M1HVcIVt\X[jdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGUu[2GmaHXybY4h[W6mIHvldoF1cW5?	MnPqNlU1OjR6OUi=
A2780	Mnf0SpVv[3Srb36gRZN{[Xl?	MoHvOU8yOC9zNTFOwG0>	Mn3QOFghcA>?		NILxb5ll\WO{ZXHz[ZMhfGinIHX4dJJme3Orb36gc4YhVi2lYXTo[ZJqdiCjbnSgWolu\W62aX6=	M{DXcFI2PDJ2OEm4
SKOV3	NIrKSJJHfW6ldHnvckBCe3OjeR?=	M{\hN\|UwOTBxMUWg{txO	M4r2XlQ5KGh?		MXzk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?	NHPMV3ozPTR{NEi5PC=>
A2780	NWXtXpRZTnWwY4Tpc44hSXO\|YYm=	MV21M\|ExNzF3IN88US=>	M3nuSFEhcA>?		MmHtbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NUfwfnJQOjV2MkS4PVg>
SKOV3	NUDN[2pwTnWwY4Tpc44hSXO\|YYm=	MUe1M\|ExNzF3IN88US=>	Ml7jNUBp		M1Xlbolv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBxNUGNVDDhcoQheC2HUlugbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3PKOFI2PDJ2OEm4
HCT-15	NXLod3ZrTnWwY4Tpc44hSXO\|YYm=	NILaXncyOC13MDFOwG0>	MXO2MVM3KGh?		MUHpcoR2[2W\|IITo[UBmgHC{ZYPzbY9vKG:oIFPPXE0zKGmwIHLveIgh\G:\|ZTDhcoQhfGmvZTDk[ZBmdmSnboSgcYFvdmW{	MXmyOVIyQDB{OB?=
HT-29	NGO2fFlHfW6ldHnvckBCe3OjeR?=	NF:4UlkyOC13MDFOwG0>	MX[2MVM3KGh?		NWH5c2ZmcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	MUeyOVIyQDB{OB?=
HSC3	M1W1eWNmdGxiVnnhZoltcXS7IFHzd4F6	MXGw5qCUPDBizszN	MWG0PEBp		NVXafYhEUUN3ME2yOU42yrFzLke4NEDPxE1?	M{nSbVI2OTl6N{i5
HSC3	MXLBdI9xfG:\|aYOgRZN{[Xl?	NE[4NHgzPSEQvF2=	MXO0PEBp		MXTpcoR2[2W\|IHHwc5B1d3Orcx?=	Mon3NlUyQTh5OEm=
HSC3	NUfjVphpTnWwY4Tpc44hSXO\|YYm=	NX3YR3lWOjVizszN	MXG0PEBp		NWPTbotR\XiqaXLpeJMhe2mpbnnmbYNidnSueTDy[YR2[2WmIH3p[5JifGmxbjDjc41jcW6nZDD3bZRpKEOHVB?=	NXzINYxMOjVzOUi3PFk>
HSC3	Ml;SSpVv[3Srb36gRZN{[Xl?	M2TG[FI2KM7:TR?=	M4nkWlQ5KGh?		NHTTcXVqdmirYnn0d{BJW0N\|IHPlcIwhcW64YYPpc44h[2:vYnnu[YQhf2m2aDDDSXQ>	MUSyOVE6QDd6OR?=
HSC3	NUTINZZ6TnWwY4Tpc44hSXO\|YYm=	M3W5WVI2KM7:TR?=	M4nrS\|czKGh?		NUjseZhK\GWlcnXhd4V{KE2PUD2yJIFv\CCPTWCtPUBxem:2ZXnud:Kh	MmryNlUyQTh5OEm=
201T	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M{fi[VczKGh?	M173bGROW09?	M3f5ZWlEPTB;NEiuOkDDvU1?	MVGyOVA2Pzl2MR?=
273T	NUn4NoN3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NVO4VFhKPzJiaB?=	NGj1UGZFVVOR	NF7FflNKSzVyPUiwMlUhyrWP	Mn3ENlUxPTd7NEG=
Hep-2	M2PufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvzN\|AwPTBxMUCwJO69VQ>?	MmDSNVIwOjRxM{[vOFghcA>?	Mn;wSG1UVw>?	NGLm[ZBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NXvrZ3ZmOjR7OUi1OlQ>
Hep-2	M13rVWFxd3C2b4Ppd{BCe3OjeR?=	NITsTGo2OCEQvF2=	M{jEPFAuPDhiaB?=	M{O5NGROW09?	MmPHbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	M3G4blI1QTl6NU[0
Hep-2	Mmn2SpVv[3Srb36gRZN{[Xl?	NUfiTZEzPTBizszN	M3ywflAuPDhiaB?=	NVKwXWRNTE2VTx?=	NF3ze45z\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?=	NF30b\|EzPDl7OEW2OC=>
Hep-2	MXHGeY5kfGmxbjDBd5NigQ>?	NH7lVFg2OCEQvF2=	Mne1NE01QCCq	M1yzVmROW09?	NFruZpRl\WO{ZXHz[ZMhfGinIH3SUmEh\XiycnXzd4lwdiCxZjDoWGVTXA>?	NInERYUzPDl7OEW2OC=>
SGC-7901	M2CyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXW4THVjOTBxNUCvNVAxKM7:TR?=	NULtWVFOOjRxNEivO\|IhcA>?	NHTtdolFVVOR	MlL5bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nIHHu[EBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	MkXPNlQ6QTJ7NUi=
MKN-45	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUexNE82OC9zMECg{txO	Ml[1NlQwPDhxN{KgbC=>	MYTEUXNQ	NHv5d2RqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	NHzVSXEzPDl7Mkm1PC=>
SGC-7901	MkXDSpVv[3Srb36gRZN{[Xl?	MUKxNE82OC9zMECg{txO	M1vKTVQ5KGh?	NWHKO2pqTE2VTx?=	MULkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NFHJeHczPDl7Mkm1PC=>
MKN-45	M33EN2Z2dmO2aX;uJGF{e2G7	NXjCepJYOTBxNUCvNVAxKM7:TR?=	M3jqOFQ5KGh?	NYrCTJpjTE2VTx?=	MWfkc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	NG\TboszPDl7Mkm1PC=>
C666-1	MYHDfZRwfG:6aXPpeJkhSXO\|YYm=	MYqyNE05OCEQvF2=	M{nlT\|I1KGh?		NHzjc2pl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	MXKyOFg2PDh\|OB?=
CNE-1	MonUR5l1d3SxeHnjbZR6KEG\|c3H5	MVeyNE05OCEQvF2=	MV[yOEBp		NX7IRmZu\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	M3:3PFI1QDV2OEO4
CNE-2	NV\xcZRIS3m2b4TvfIlkcXS7IFHzd4F6	NXvXZ2pPOjBvOECg{txO	NHj3ZlIzPCCq		M4DT[IRm[3KnYYPld{Bkd2yxbomg[o9zdWG2aX;uJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyxsA>	NUDNe45[OjR6NUS4N\|g>
C666-1	NFjrd3NEgXSxdH;4bYNqfHliQYPzZZk>	NGLXNmw3OCEQvF2=	NFfVR4M4KGR?		MUTlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?=	NVjpWY1uOjR6NUS4N\|g>
CNE-1	MUPDfZRwfG:6aXPpeJkhSXO\|YYm=	NXe0[FE{PjBizszN	M2fYN\|ch\A>?		MXLlcohidmOnczDyZYRq[XSrb36gZ5l1d3SxeHnjbZR6KHSqcn;1[4ghS0:[LUKt[IVx\W6mZX70JI1idm6nch?=	MWGyOFg2PDh\|OB?=
SNU-1041	M3q1b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOwMVQxKM7:TR?=	NUXhNoJ{PDhiaB?=		NITIdGpqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M3;jW\|I1Pjl{N{Cz
SNU-1041	NX7rcXVHTnWwY4Tpc44hSXO\|YYm=	NF\UV4kzOC9\|MDFOwG0>	NFr0RZQ1KGh?		NFzDOWRqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	M3jwN\|I1Pjl{N{Cz
SNU-1041	M3\FcWZ2dmO2aX;uJGF{e2G7	NX\2dmxJOC12MDFOwG0>	NFi1VW41KGh?		NFnnT2J2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?=	Ml\oNlQ3QTJ5MEO=
SGC-7901	NXq3UIRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2K4RVUxNTF{NTFOwG0>	M2fUe\|I1NzR6L{eyJIg>		NFW1e5dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M4PLXFI1Pjd4M{m0
SGC-7901	MWXBdI9xfG:\|aYOgRZN{[Xl?	MXGxNFAh\|ryP	Mnm4O\|IhcA>?		MnjLbY5lfWOnczDhdI9xfG:\|aYO=	MYGyOFY4PjN7NB?=
SGC-7901	MkHlSpVv[3Srb36gRZN{[Xl?	NGPVW204PS9zMECvNVI2KM7:TR?=	NWT1NohiOjRxNEivO\|IhcA>?		NXqxcoxlcW6lcnXhd4V{KGOjc4Dhd4UuQCCjbnSgMVkhdVKQQTDlfJBz\XO\|aX;uJIlvKGKxdHigeIlu\SCjbnSg[I9{\SCvYX7u[ZI>	MnviNlQ3PzZ\|OUS=
LMeC	M4jsV2Z2dmO2aX;uJGF{e2G7	MXGyNE82OCEQvF2=	MYO0PEBp		M2\meIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw	MUGyOFY2Pjd2Nh?=
CMeC-1	M4[1eWNmdGxiVnnhZoltcXS7IFHzd4F6	NV;DdIZyOjBxNUCg{txO	MmTXOFghcA>?		MoD0bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NWLRdFZnOjR4NU[3OFY>
LMeC	NX;4ZVh3S2WubDDWbYFjcWyrdImgRZN{[Xl?	NYLyTGZMOjBxNUCg{txO	MVq0PEBp		M2j0d4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	Mn7BNlQ3PTZ5NE[=
CMeC-1	Mn;ESpVv[3Srb36gRZN{[Xl?	MnXUNlAwPTBizszN	MVK0PEBp		M4nzTIlv\HWlZYOgS\|EuWyCjcoLld5Q>	M33jcVI1PjV4N{S2
LMeC	NGHkOFlHfW6ldHnvckBCe3OjeR?=	NVHOT\|VSOjBxNUCg{txO	NIXQSJg1QCCq		NWHMXHBPcW6mdXPld{BIOS2VIHHydoV{fA>?	NYnWXWxZOjR4NU[3OFY>
CMeC-1	MV;GeY5kfGmxbjDBd5NigQ>?	NY\3UXF1OjBxNUCg{txO	M3jKSlQ5KGh?		MVrk[YNz\WG\|ZYOgeIhmKGyndnXsd{Bw\iCleXPsbY4hTDFiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NGi5OWQzPDZ3Nke0Oi=>
LMeC	MXfGeY5kfGmxbjDBd5NigQ>?	M{L4V\|IxNzVyIN88US=>	MWi0PEBp		M4rJWYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIHP5Z4xqdiCGMTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MX:yOFY2Pjd2Nh?=
CMeC-1	M1\Oc2Z2dmO2aX;uJGF{e2G7	MlGzNlAwPTBizszN	NHTq[5I1QCCq		NIHtOG9qdmS3Y3XzJINie3Cjc3WtN{Bi[3SrdnH0bY9v	MX[yOFY2Pjd2Nh?=
LMeC	M3rP[2Z2dmO2aX;uJGF{e2G7	MoTTNlAwPTBizszN	M{DWUVQ5KGh?		MWPpcoR2[2W\|IHPhd5Bie2VvMzDhZ5RqfmG2aX;u	NEDtU44zPDZ3Nke0Oi=>
OVCAR-3	NHjGVoxE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NUTOdJNiOTBiwsXN	MVmxJIg>		MVflcohidmOnczDwZYNtcXSjeHXsMYlv\HWlZXSgc5ZiemmjbjDjZY5k\XJiY3XscEBl\WG2aNMg	MmfQNlQ2OjB{Mke=
OVCAR-3	NGe0VWpCeG:ydH;zbZMhSXO\|YYm=	NEXpOmIyOCEEtV2=	NX\HZ\|MxOSCq		Mn;RdJJwdW:2ZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFxd3C2b4Ppd:Kh	MXKyOFUzODJ{Nx?=
OVCAR-3	NHT5ZpdHfW6ldHnvckBCe3OjeR?=	M4\TSlExKML3TR?=	NVnIUol[OSCq		Mnvn[Y5p[W6lZYOgdIFkdGm2YYjlcE1qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\S17wrC=	Mn\INlQ2OjB{Mke=
OVCAR-3	MYfGeY5kfGmxbjDBd5NigQ>?	NX\TfHhGOTBiwsXN	NGDaO3IyKGh?		Mlvq[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs	NEfvdXUzPDV{MEKyOy=>
OVCAR-3	MWfGeY5kfGmxbjDBd5NigQ>?	M1XLNlExKML3TR?=	MXGxJIg>		M2Da[4lvcGmkaYTzJJBi[2yrdHH4[YwucW6mdXPl[EBCc3RicHjvd5Bpd3K7bHH0bY9v	NHmyVoIzPDV{MEKyOy=>
CF33	NHTSUYJHfW6ldHnvckBCe3OjeR?=	MkPkNVAxKM7:TR?=	Mn7GNlQhcA>?		MlTzbY5lfWOnczDkc5dvemWpdXzheIlwdiCxZjDDU3guOiCycn;0[YlvKGW6cILld5Nqd25?	NVX5R45QOjR3MEO3PFI>
CF33	NIL0SHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7N[\|QyOC1zMECg{txO	MlT4NE01KGR?		M3nj[4lvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M2i2SVI1PTB\|N{iy
CF33	NETwb\|NHfW6ldHnvckBCe3OjeR?=	MkjINVAuOTByIN88US=>	NWX0enNqPC1{NDDo		M4DuN4Rm[3KnYYPld{Bk\WyuczDpckB1cGViUzDwbIF{\SCjbnSgbY5kemWjc3XzJINmdGy\|IHnuJGcxN0dzIHHydoV{fA>?	MXSyOFUxOzd6Mh?=
LNCaP	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGX2dlEzNzVxMUCg{txO	M{TaNFk3KGh?		MUHpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XSxco\hd5RifGmw	NGixPYwzPDJ7Nkm3PC=>
LNCaP	NGXaT4RCeG:ydH;zbZMhSXO\|YYm=	NY\KT3FQOi93L{GwJO69VQ>?	NWDRO2hNQTZiaB?=		MU\pcoR2[2W\|IHHwc5B1d3OrczDjc41jcW6nZDD3bZRpKGG2b4L2ZZN1[XSrbh?=	M3jGSVI1Ojl4OUe4
PC-3	M3LBeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fyflAuPTBizszN	NXT2XldJPDkkgJno		MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	MW[yOFEzPzh6Mh?=
PC-3	NEnlUldE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NFjJNGExNTFyMDFOwG0>	NWjNeXNSPzJiaB?=		NXPs[Itw\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	Ml;INlQyOjd6OEK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Ethanol	33 mg/mL (86.53 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	SC 58635
Smiles	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526197	Enrolling by invitation	Drug: ALXN1840\|Drug: Celecoxib	Wilson Disease	Alexion Pharmaceuticals	July 8 2020	Phase 1
NCT04447261	Recruiting	Drug: BI 1356225\|Drug: Placebo	Obesity	Boehringer Ingelheim	June 30 2020	Phase 1
NCT03896113	Recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	November 13 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
A-438079 HCl ^New

A-438079 HCl is a potent, and selective P2X7 receptor antagonist with pIC50 of 6.9.
Indomethacin

Indomethacin is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin

Aspirin (Acetylsalicylic acid) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Rofecoxib

Rofecoxib (MK-0966) is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen

Ibuprofen (Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib